Sellas Life Sciences Group Inc Total Assets
Sellas Life Sciences Group Inc total assets. Based on the latest financial reports, Sellas Life Sciences Group Inc (SLS) holds total assets worth $145.38 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see SLS cash generation efficiency for how efficiently the company converts equity into cash flow.
Total Assets of Sellas Life Sciences Group Inc (2006–2025)
Total assets of Sellas Life Sciences Group Inc from 2006 to 2025. This chart illustrates how Sellas Life Sciences Group Inc's total assets have evolved over time, based on quarterly financial data. See SLS live share price for real-time trading data and today's change.
Sellas Life Sciences Group Inc - Asset Composition Analysis
Sellas Life Sciences Group Inc Total Assets Breakdown (December 2025)
Sellas Life Sciences Group Inc total assets breakdown as of December 2025. Sellas Life Sciences Group Inc's total assets of $145.38 Million consist of 96.0% current assets and 4.0% non-current assets. Explore SLS working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 91.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $1.91 Million | 2.4% |
Asset Composition Trend (2006–2025)
This chart illustrates how Sellas Life Sciences Group Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sellas Life Sciences Group Inc's current assets represent 96.0% of total assets in 2025, a decrease from 100.0% in 2006.
- Cash Position: Cash and equivalents constituted 91.8% of total assets in 2025, down from 100.0% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2006.
- Asset Diversification: The largest asset category is goodwill at 2.4% of total assets.
Sellas Life Sciences Group Inc Competitors by Total Assets
Key competitors of Sellas Life Sciences Group Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Sellas Life Sciences Group Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 18.83 | 4.91 | 5.45 |
| Quick Ratio | 18.83 | 4.91 | 5.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $134.94 Million | $23.45 Million | $23.66 Million |
Sellas Life Sciences Group Inc - Advanced Valuation Insights
This section examines the relationship between Sellas Life Sciences Group Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 20.48 |
| Latest Market Cap to Assets Ratio | 24.95 |
| Asset Growth Rate (YoY) | 303.2% |
| Total Assets | $78.34 Million |
| Market Capitalization | $1.95 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Sellas Life Sciences Group Inc's assets at a significant premium (24.95x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Sellas Life Sciences Group Inc's assets grew by 303.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Sellas Life Sciences Group Inc (2006–2025)
The table below shows the annual total assets of Sellas Life Sciences Group Inc from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $78.34 Million | +303.18% |
| 2024-12-31 | $19.43 Million | +212.46% |
| 2023-12-31 | $6.22 Million | -70.31% |
| 2022-12-31 | $20.94 Million | -20.75% |
| 2021-12-31 | $26.43 Million | -42.61% |
| 2020-12-31 | $46.05 Million | +177.25% |
| 2019-12-31 | $16.61 Million | -1.81% |
| 2018-12-31 | $16.91 Million | -49.55% |
| 2017-12-31 | $33.53 Million | -49.06% |
| 2016-12-31 | $65.81 Million | -19.88% |
| 2015-12-31 | $82.14 Million | +2.06% |
| 2014-12-31 | $80.49 Million | -8.51% |
| 2013-12-31 | $87.98 Million | +60.00% |
| 2012-12-31 | $54.99 Million | +77.56% |
| 2011-12-31 | $30.97 Million | +314.23% |
| 2010-12-31 | $7.48 Million | +19.58% |
| 2009-12-31 | $6.25 Million | -39.65% |
| 2008-12-31 | $10.36 Million | -14.72% |
| 2007-12-31 | $12.15 Million | +607250.00% |
| 2006-12-31 | $2.00K | -- |
About Sellas Life Sciences Group Inc
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or … Read more